StemSynergy Therapeutics
StemSynergy Therapeutics is a biotechnology company focused on the discovery and development of novel therapeutics targeting mechanisms fundamental to cancer, such as Wnt, Notch, and Myc signaling. They aim to identify drug targets in these pathways that provide greater efficacy and minimal toxicity, with a robust pipeline including six therapeutic agents, and hold multiple patents for their breakthrough technologies.
Industries
Nr. of Employees
small (1-50)
StemSynergy Therapeutics
1951 NW 7th Avenue, Suite 300, Miami, FL 33136
Patents
Inhibitors of the notch transcriptional activation complex and methods for use of the same
US-12275725-B2
View DetailsMethods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell
US-11834446-B2
View DetailsMethods and compositions useful in treating cancer and reducing WNT mediated effects in a cell
US-11512081-B2
View DetailsMethods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell
US-10975067-B2
View DetailsMethods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell
US-9862714-B2
View DetailsMethods and compositions useful in treating cancer and reducing WNT mediated effects in a cell
US-9416101-B2
View Details
Inhibitors of the notch transcriptional activation complex and methods for use of the same
US-12275725-B2
View DetailsMethods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell
US-11834446-B2
View DetailsMethods and compositions useful in treating cancer and reducing WNT mediated effects in a cell
US-11512081-B2
View DetailsMethods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell
US-10975067-B2
View DetailsMethods and compositions useful in treating cancer and reducing Wnt mediated effects in a cell
US-9862714-B2
View DetailsMethods and compositions useful in treating cancer and reducing WNT mediated effects in a cell
US-9416101-B2
View DetailsProducts
Preclinical therapeutic pipeline
A preclinical portfolio of therapeutic agents (reported as six agents) developed to target core oncogenic pathways such as Wnt, Notch, and Myc.
Preclinical therapeutic pipeline
A preclinical portfolio of therapeutic agents (reported as six agents) developed to target core oncogenic pathways such as Wnt, Notch, and Myc.
Services
Internal discovery and preclinical advancement of therapeutic candidates targeting oncogenic signaling pathways, including lead identification, medicinal chemistry, in vitro and in vivo validation.
Internal discovery and preclinical advancement of therapeutic candidates targeting oncogenic signaling pathways, including lead identification, medicinal chemistry, in vitro and in vivo validation.
Expertise Areas
- Oncogenic signaling pathway targeting (Wnt, Notch, Myc, Hedgehog, Hippo-YAP)
- Small-molecule drug discovery and medicinal chemistry
- Preclinical development and IND-enabling studies
- In vivo tumor models and pharmacology
Key Technologies
- Small-molecule high-throughput screening
- Targeted pathway modulation (Wnt/Notch/Myc/Hedgehog/Hippo-YAP)
- Organocatalysis and enantioselective synthesis
- Isotopic labeling for mass spectrometry